Gemysetin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gemysetin

Quick Facts

Property Description
Active ingredient Chloramphenicol
Form Eye Ointment, Eyedrops, Oral capsules, Injectable solution
Pharmacological class Antibiotic (Broad-spectrum)
General Purpose Infection control / Combating bacteria
Origin Synthetic

What Type of Medicine is Gemysetin and What is it Made Of?

Gemysetin is a trade name preparation containing the active ingredient Chloramphenicol, classified as a prescription-only, broad-spectrum antibiotic within the miscellaneous antibiotics pharmacological group. The medicine is characterized as a single product, typically utilizing Chloramphenicol as its only principal therapeutic agent. Although the compound was originally isolated from the bacterium Streptomyces venezuelae, the substance used in modern pharmaceuticals is produced synthetically. This agent is effective against a wide variety of susceptible Gram-positive and Gram-negative bacteria.

How Does Chloramphenicol Function at a Basic Level?

The general purpose of Chloramphenicol is to provide effective infection control by halting bacterial growth across various infections caused by bacteria. Its primary mode of action is bacteriostatic, preventing bacterial proliferation. The mechanism involves its function as a protein synthesis inhibitor, achieved by binding reversibly to the bacterial 50S ribosomal subunit, which prevents the formation of peptide bonds. This selective blockade limits the bacteria's ability to create essential proteins, which is crucial for managing serious bacterial infections.

What Forms of Gemysetin Are Available?

Gemysetin is available in various dosage forms tailored for different routes of administration, distinguishing it as a versatile antibiotic. The most frequent presentation includes the sterile Eye Ointment or eyedrops for localized surface treatment via the ophthalmic route. However, Chloramphenicol is also formulated into eardrops for the otic route, oral capsules, and an injectable solution for the intravenous route. The availability of these multiple forms ensures the medicine can be delivered appropriately, whether for localized needs, such as superficial ophthalmic infections, or for treating more serious infections.

Regulatory References

  1. Chloramphenicol Mechanism of Action
  2. Chloramphenicol Clinical Use

What side effects are possible with Gemysetin?

Gemysetin is associated with specific adverse reactions and safety restrictions that are primarily related to its active component, Chloramphenicol. Factual information on its safety profile is derived from official regulatory documents.

Serious and Clinically Significant Risks

Gemysetin carries a risk of serious and potentially fatal blood dyscrasias, including aplastic anemia (a rare but severe type of bone marrow failure), hypoplastic anemia, thrombocytopenia, and granulocytopenia. This risk has been reported following both short-term and prolonged use, and cases of aplastic anemia later terminating in leukemia have been documented. Due to systemic absorption even from topical forms, this risk is a key safety consideration.

Other Documented Adverse Reactions

Adverse reactions that have been reported include sensitivity reactions such as transient irritation, burning, stinging, itching, and dermatitis at the application site. Other documented effects are linked to systemic exposure, including gastrointestinal issues like nausea, vomiting, and diarrhea, as well as neurological effects such as optic neuritis and peripheral neuropathy (tingling or numbness in the extremities), particularly with prolonged treatment.

Safety Limitations and Monitoring

  • Contraindications: The medicine is contraindicated in individuals with known hypersensitivity to the drug or a personal or family history of blood dyscrasias, including aplastic anemia.
  • Pediatric Population: Use is not recommended in children under two years of age due to very rare reports of Gray Baby Syndrome and leukemia.
  • Pregnancy and Breastfeeding: Because the active component is absorbed systemically, crosses the placenta, and diffuses into breast milk, the drug is generally not recommended during pregnancy or breastfeeding.
  • Monitoring: Given the risk of serious blood disorders, adequate blood studies may be required during treatment to monitor for hematologic changes.

High-Level Safety Summary

Classification Detail
Adverse Reactions (Very Rare) Hematologic events (bone marrow depression, aplastic anemia, death)
Adverse Reactions (Not Known) Sensitivity reactions (irritation, burning, stinging, itching, dermatitis)
Key Safety Restriction Contraindicated in personal/family history of blood dyscrasias

The overall safety profile highlights the importance of recognizing the potential for rare but life-threatening hematologic toxicities, a risk that necessitates contraindications against use in patients with a predisposition to blood disorders and requires careful use in all age groups, particularly infants and children under two.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Gemysetin (Chloramphenicol) focuses on acute, dose-dependent toxicity, demanding immediate medical intervention for potential severe outcomes.

Domain Official Regulatory Statement
Documented Overdose Presentations Symptoms include gastrointestinal disturbance (nausea, vomiting) and neurological effects (headache, confusion, delirium).
Physiological Systems Affected Hematological system (reversible bone marrow depression, anemia, leukopenia) and Cardiovascular system (hypotension, circulatory collapse).
Population-Specific Overdose Notes Neonates and infants are at high risk for the life-threatening Grey Baby Syndrome, characterized by symptoms such as progressive pallor, cyanosis, abdominal distension, and circulatory collapse.
Emergency-Response Statements Seek immediate medical attention and/or contact a Poison Control Center immediately upon suspicion of overdose or onset of severe manifestations.

Official Overdose Statements:

  • Overdose is associated with high plasma concentrations and presents with documented systemic manifestations, including signs of bone marrow depression.
  • Immediate medical care is required for any suspected overdose event due to the risk of severe or life-threatening outcomes, particularly Grey Baby Syndrome in vulnerable populations.
  • No specific antidote is known; therefore, management is directed toward symptomatic and supportive treatment, including continuous hematological monitoring and potential need for specialized procedures like exchange transfusion in severe cases.

Connection to the Overall Overdose Profile: The official documents define the overdose profile by listing specific dose-related signs and classifying Grey Baby Syndrome as a severe risk in high-risk populations. The lack of a specific antidote necessitates that the sole mandated action is to seek urgent professional medical assistance for supportive care and continuous observation.

Therapeutic Uses of Gemysetin

Gemysetin is commonly used across distinct clinical settings depending on the type and location of the infection.

This medicine may be part of symptomatic management for acute, localized bacterial infections of the external eye (conjunctivitis) and the outer ear canal (otitis externa). It is also reserved for managing select serious systemic infections, including Typhoid Fever and certain forms of Bacterial Meningitis. In clinical scenarios where the infection is caused by multi-drug resistant bacteria or highly specific pathogens like those involved in Rickettsial infections, Gemysetin may be relevant when additional symptomatic support is needed.

This approach is centered on patient comfort:

“It is applied across domains where additional symptomatic support is needed to help address symptom clusters such as intense redness, purulent discharge, and localized pain, which contributes to improved comfort during these acute, disruptive episodes.”

In these situations, the medicine supports the body in addressing the causative bacteria and contributes to maintaining a sense of stability when symptoms create noticeable physiological strain.

Quick Fact: Symptom Management Domains
This medicine is commonly used to help manage symptoms related to physical discomfort in the eye and ear, and assists with providing supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. clinical documentation

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Gemysetin — Official Regulatory Information

Gemysetin (which contains Chloramphenicol) is available as a topical eye ointment. Eligibility for use is determined by known medical conditions and age, as defined in official product labeling.


Eligibility Scope

Classification Eligibility Rules (Based on Regulatory Documents)
Populations for whom use is contraindicated Known hypersensitivity to Chloramphenicol or any excipients. Known personal or family history of blood dyscrasias, including aplastic anemia.
Age-related eligibility rules Use should not be established in children under 2 years of age (due to very rare reports of serious conditions, including gray baby syndrome and leukemia).
Condition-specific eligibility rules Use requires special consideration in cases of liver impairment, where the drug's half-life is increased.
Pregnancy and lactation eligibility status Should not be used during pregnancy as systemic absorption can occur and the drug crosses the placenta. Should not be used during breast-feeding as it passes into breast milk.

Resulting Eligibility Structure

The primary constraints on Gemysetin use are defined by two major contraindications: a history of blood disorders and allergic reactions to the medication. Furthermore, its use is formally restricted for the pediatric population under 2 years old and is explicitly not recommended during pregnancy or lactation. These restrictions define the official regulatory scope of who should not take the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Gemysetin (Chloramphenicol) has a documented profile of interactions that primarily centers on drug metabolism inhibition and pharmacodynamic synergy, as established by regulatory authorities.


Pharmacokinetic and Contraindicated Combinations

Gemysetin is a potent inhibitor of key drug-metabolizing enzymes, notably CYP3A4 and CYP2C19. This inhibition decreases the clearance of many co-administered substances, leading to a documented increased plasma concentration or exposure.

Regulatory documents formally classify co-administration with numerous CYP3A4 substrates, including Lurasidone, as contraindicated. This restriction applies to a wide range of agents such as Alfuzosin, Triazolam, and Voclosporin, due to the serious risk of elevated drug levels.

Category Officially Documented Interacting Substances
Exposure Increase Phenytoin, Warfarin, Cyclosporine, Tacrolimus, Tolbutamide
Contraindicated Lurasidone, Alfuzosin, Triazolam, and numerous other CYP3A4 substrates

Pharmacodynamic and Other Interactions

Co-administration with other medicines liable to depress bone marrow function must be avoided due to an officially documented additive risk of severe hematological toxicity. This shared toxicity profile involves medicines such as Azathioprine and Rifampicin. Furthermore, Gemysetin may decrease the therapeutic efficacy of live bacterial vaccines (e.g., Typhoid Vaccine, Live). Interaction caution is also noted for specific populations, including neonates and patients with hepatic impairment, due to their reduced ability to metabolize the medicine.

Mechanism of Action

Targeted Inhibition of Bacterial Protein Synthesis

Chloramphenicol (Gemysetin) acts by engaging a molecular mechanism: it functions as a reversible inhibitor that targets the bacterial 50S ribosomal subunit. By binding to the peptidyl transferase center (PTC), the drug physically prevents the formation of peptide bonds, thereby immediately halting the creation of all new essential bacterial proteins. This targeted molecular blockade imposes a bacteriostatic effect, meaning it stops susceptible bacteria from multiplying.


Cascade to Physiological Cessation of Growth

The cessation of bacterial protein synthesis triggers a physiological cascade. The inability of the pathogen to synthesize key enzymes and structural components results in the arrest of its growth and proliferation. This physiological change—reducing the viable pathogen load—sets the required biological condition for the host's natural immune mechanisms to clear the remaining, non-multiplying bacterial population.


️ Mechanisms of Resistance and Specificity

A functional constraint on this mechanism is the development of resistance, primarily through the bacterial enzyme Chloramphenicol acetyltransferase (CAT), which inactivates the drug, or by efflux pumps that expel the drug from the cell. Furthermore, the drug’s potential to bind to mammalian mitochondrial ribosomes represents a specificity limitation, though its primary, intended action remains targeted against the bacterial 70S ribosome.

Dosage and Administration Information

How to Use Gemysetin

Gemysetin administration follows distinct protocols depending on the chosen route. For treating serious systemic infections, the drug is administered via intravenous (IV) injection or slow infusion, or less commonly, through oral capsules. For localized surface conditions, it is applied topically as ophthalmic drops/ointment or otic drops.


Dosage and Frequency Principles

Systemic dosing is typically calculated based on body weight, with a standard regimen of 50 mg/ kg of body weight per day. This total daily dose is administered in four equal portions given at regular 6-hour intervals to maintain consistent levels of the active substance in the body. In exceptional situations involving severe, life-threatening infections, the dose may temporarily be increased up to 100 mg/ kg/ day but must be reduced as soon as possible. The duration of systemic treatment is generally defined by clinical response, continuing for 8 to 10 days after the resolution of fever.


Administration Specifics and Adjustments

Oral capsules are recommended to be taken on an empty stomach, meaning one hour before or two hours after a meal. For the injectable form, the powder must be reconstituted to a 100 mg/ mL solution prior to being administered by slow intravenous injection or infusion. Systemic dosage is reduced for patients with hepatic or renal impairment, and specific low-dose regimens are used for neonates and premature infants due to their reduced ability to metabolize the medicine.

Recent Clinical Evidence

Research Evidence Overview of Studies for Gemysetin

Evidence for use in Superficial Ophthalmic Infections

Research has examined Gemysetin's use for treating certain superficial ophthalmic infections, particularly those involving the conjunctiva or cornea caused by susceptible organisms like Staphylococcus aureus or Haemophilus influenzae. Studies report how symptoms evolved in the observed populations, with short-term clinical trials focusing on outcomes related to systemic or functional imbalance, such as the microbiological clearance of pathogens. Findings describe patterns observed in these studies, where treatment was evaluated in populations presenting with acute or episodic changes in eye discomfort.

Long-term Studies and Follow-up Data

Research describes short-term data (typically five days) for treating acute infections, which is relevant in trials assessing short-term or episodic symptom patterns. Follow-up durations were limited in the primary clinical research. Long-term effects are not fully established, and there is limited information regarding the potential durability of observed changes or the incidence of long-term adverse events with repeated or extended use.

Evidence in Special Populations

Studies explored the use of Gemysetin in adults and children aged two years and older. However, data for certain groups remain insufficient. For instance, few data are available specifically for geriatric patients or those with pre-existing kidney or liver impairment. Gemysetin was observed in some studies to be absorbed systemically following topical application, and evidence indicates that its use may be contraindicated during pregnancy or lactation due to potential risks identified in related compound research.

What is Still Uncertain About Gemysetin Research

Evidence is limited for treating infections caused by certain pathogens, such as Pseudomonas aeruginosa and Serratia marcescens. While research provides context regarding symptom evolution, it does not determine whether an individual will respond similarly. Comparative evidence is lacking for many common alternative treatments. Findings describe group patterns, not personal outcomes, and subgroup findings are uncertain for many comorbid conditions, highlighting areas where research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Gemysetin (FAQ)

Q: How quickly does Gemysetin start working?

A: According to official information, the medicine’s mechanism of action begins immediately at the cellular level by blocking bacterial protein synthesis. However, the time it takes for a person to notice clinical improvement in their symptoms depends on the type of infection being treated and the specific route of administration.

Q: What happens if I miss a dose of Gemysetin?

A: Patient information leaflets typically state that if a dose is missed, it should be administered as soon as it is remembered. If it is nearly time for the next scheduled dose, patients are usually advised to skip the missed dose and continue the regular schedule. Taking two doses at the same time to make up for a missed dose is generally not recommended.

Q: Is Gemysetin safe to take with common pain relievers like ibuprofen?

A: Official drug labeling focuses on interactions with prescription medicines that affect certain liver enzymes or blood cell production. Common over-the-counter pain relievers like ibuprofen are not specifically listed as known contraindications. However, for safety, it is important that a healthcare provider is made aware of all medicines being taken, including non-prescription products.

Q: Why is Gemysetin prescribed instead of other similar drugs?

A: Regulatory documents indicate that Gemysetin is reserved for serious infections caused by organisms susceptible to its effects, particularly when other agents considered less hazardous are ineffective or contraindicated. Due to the risk of serious side effects, this medicine is generally not used for minor infections.

Q: Is Gemysetin available over the counter anywhere?

A: Gemysetin is primarily classified as a prescription-only medicine (POM) for both systemic use (capsules, injections) and topical use in many regions due to the risk of serious side effects. While over-the-counter access to the eye drops may be allowed for adults and children over two years in some locations, prescription status remains standard for most forms.

Q: Can I drink alcohol while I'm on Gemysetin?

A: In general, official drug sources do not list alcohol as a specific substance to avoid while using Gemysetin, and consumption is often considered acceptable. Any specific guidance provided by the prescriber supersedes general information.

Q: Can I stop taking Gemysetin suddenly if I feel better?

A: Official product information advises against stopping the medication prematurely. The entire prescribed course of therapy should be completed, even if symptoms improve quickly, as stopping early may risk the return of the infection and contribute to antibiotic resistance.

Q: Are there any known interactions between Gemysetin and herbal products?

A: Regulatory documents primarily focus on interactions with prescription and non-prescription drugs, so information on specific herbal or complementary products is not comprehensively listed. For safety, it is necessary to make the healthcare professional aware of all herbal products or supplements being taken.

Q: Why are there different strengths or forms of Gemysetin?

A: The different forms, such as drops, capsules, and injections, are designed to deliver the medicine to the specific location of the infection. For example, the eye drops are used for local surface infections, whereas the injectable solution is used for serious systemic infections.

Q: Is Gemysetin used for chronic conditions or only short-term?

A: Official prescribing information indicates that Gemysetin is generally reserved for the treatment of acute, serious bacterial infections. Due to the risk of rare but serious hematological toxicity, its use is typically restricted to short courses of therapy.

Q: What if I take Gemysetin and feel no change?

A: If no clinical improvement is observed after a few days of treatment, a healthcare professional should be contacted. Lack of response may suggest the infection is caused by a non-susceptible organism, and continued monitoring, potentially including blood tests, may be required.

Q: Can Gemysetin be crushed or split?

A: Official administration instructions specify how the injectable powder must be reconstituted and advise that oral capsules should be taken intact on an empty stomach. There are no official recommendations for crushing or splitting the capsules, which suggests they should be swallowed whole as intended.

Q: What is the average duration of treatment with Gemysetin?

A: The total duration of treatment is typically determined by the type of infection and the patient's clinical response. For serious systemic infections, regulatory documents state that therapy often continues for 8 to 10 days after the resolution of fever, usually resulting in a short treatment course.

Q: Can Gemysetin affect your sleep?

A: Official drug labeling lists certain neurotoxic reactions that have been reported, including headache, mild depression, and mental confusion. These effects on the central nervous system (CNS) could potentially lead to changes in sleep patterns.

Q: Why do some people say Gemysetin makes them feel 'off'?

A: Official labeling documents common adverse effects that could contribute to a generalized feeling of being unwell. These include gastrointestinal issues like nausea, vomiting, and diarrhea, as well as neurotoxic reactions such as headache and mental confusion.

Q: What should I do if a side effect is bothering me?

A: If a side effect becomes bothersome or severe, or if signs of a serious allergic reaction occur, the medication should be stopped and professional medical advice should be sought.

Q: Is it normal to feel tired after starting Gemysetin?

A: Tiredness itself is not specifically listed as a common side effect in official documents. However, certain documented adverse effects, such as anemia (a blood disorder), or generalized effects like mild depression, could potentially cause feelings of tiredness or weakness.

Q: Is Gemysetin habit-forming or addictive?

A: Gemysetin is classified as an antibiotic. It is not listed as a controlled substance by regulatory bodies, which means it is not considered to have a potential for abuse or to be habit-forming.

Q: Has Gemysetin been subject to any recalls or warnings?

A: In the past, the FDA determined that certain oral forms of Chloramphenicol (the active ingredient in Gemysetin) were withdrawn from sale. This was done for safety reasons, specifically due to the high risk of fatal aplastic anemia associated with those forms.

Q: How is Gemysetin eliminated from the body?

A: According to official pharmacological information, the drug is primarily processed by the liver and eliminated from the body by the kidneys. For this reason, dose adjustments are typically required for patients with documented hepatic (liver) impairment.

Q: Does Gemysetin change your mood or behavior?

A: Official drug labeling reports that neurotoxic reactions, including 'mild depression' and 'mental confusion,' have been described in some patients receiving this medicine.

Q: Is it possible to be allergic to Gemysetin?

A: Yes, known hypersensitivity to the drug is a formal contraindication. Signs of an allergic reaction, such as a rash, swelling (angioedema), or fever, have been reported in official documents.

Q: What is the patent status or exclusivity period for Gemysetin?

A: The active ingredient, Chloramphenicol, is an older medicine that is now off-patent, and generic versions exist. However, due to its safety profile, regulatory bodies have restricted the approval of certain generic forms based on the specific route of administration.

How should Gemysetin be stored and disposed of?

The official storage and disposal requirements for Gemysetin (Chloramphenicol) are specific to the dosage form, ensuring the medicine's stability and public safety.

Storage Conditions

Requirement Official Instruction
Temperature Store most forms below 25°C (77°F). Some ophthalmic solutions require refrigeration, 2°C to 8°C, and must not freeze.
Protection Keep in the original container/carton and protected from light. Keep the container tightly closed.
Stability Limit Ophthalmic solution must be discarded 28 days after first opening.

Disposal and Safety

Gemysetin must be stored out of the sight and reach of children. Unused or expired product must be disposed of according to local requirements and should not be thrown away via wastewater or regular household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gemysetin found in:

A-Z Index: